Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours
- 31 January 2000
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 36 (1), 128-136
- https://doi.org/10.1016/s0959-8049(99)00230-0
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogsZeitschrift für Krebsforschung und Klinische Onkologie, 1999
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Synthesis and In Vitro Evaluation of New Potent Antagonists of Growth Hormone-Releasing Hormone (GH-RH)Peptides, 1997
- Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormoneBritish Journal of Cancer, 1997
- Induction and involvement of endogenous IGF-I in pancreas regeneration after partial pancreatectomy in the dogJournal of Endocrinology, 1996
- Inhibition of Growth of Human Osteosarcomas by Antagonists of Growth Hormone-Releasing HormoneJNCI Journal of the National Cancer Institute, 1995
- No standard treatment is available for advanced pancreatic cancerEuropean Journal Of Cancer, 1995
- A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesisNature, 1994
- Hypothalamic hormonesAnti-Cancer Drugs, 1994
- Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters events that accompany tumor regressionCancer, 1990